Anika Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Anika Therapeutics Inc 's ROA in the second quarter of 2026?
Anika Therapeutics Inc recorded a cumulative net loss of $-4 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -1.99%.

However, within the Healthcare sector 234 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3023, from total ROA ranking in the first quarter of 2026 at 3511.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-14.66 %	-5.89 %	4.94 %	-7.78 %	0.36 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-11	-11	-33	-61
Return On Assets (TTM)	-1.99 %	-5.55 %	-5.39 %	-16.53 %	-29.75 %
ANIK's Total Ranking	# 3023	# 3511	# 3482	# 3783	# 3758
Total Assets (TTM) in million	203	179	190	189	238
Seq. Total Assets Change	13.16 %	-5.72 %	0.44 %	-20.35 %	24.79 %
Seq. Net Income Change	-	-	-	-	-

ANIK's 5 Years Annual ROA >> Back to ANIK Management Effectiveness >> Compare ANIK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 73
Sector	# 235
Overall	# 2748

Return On Assets Statistics
High	Average	Low
21.59 %	2.2 %	-37.93 %
(Jun 30 2014)		(Sep 30 2024)

News about Anika Therapeutics Inc Return on Assets ROA

Anika Therapeutics Inc. Strategically Divests Subsidiaries to Focus on Profitable OA Pain Management Amid Financial Losses,

Anika Therapeutics Inc. Strategic Shift Amid Financial ChallengesIn a strategic maneuver aligned with its long-term vision, Anika Therapeutics Inc. a leading name in joint preservation and early intervention orthopedics, has announced a significant update to its business strategy. This includes the sale of its subsidiary, Arthrosurface, and the impending divestment of Parcus Medical. This strategic refocus aims to enhance their portfolio in profitable, hyaluronic acid-driven osteoarthritis (OA) pain management and to capitalize on the growth potential of regenerative solutions. Facts and Developments1. Strategic Divestitures: - Anika Therapeutics is divesting from Arthrosurface and plans to sell Parcus Medical. - The company’s focus will now remain on optimizing its portfolio around hyaluronic acid solutions for OA pain management and expanding its regenerative solutions segment, which are seen as high-growth areas.2. Financial Performance: - Anika recorded a cumulative net loss of $74 million in the 12 months leading to the second quarter of 2024. - The loss has translated into a negative return on assets (ROA) of -29.11%. - Despite this challenging financial landscape, the company s overall ROA ranking has slightly improved from 3,499 in Q1 2024 to 3,428 in Q2 2024. 3. Market Context: - In the healthcare sector, 387 companies recorded higher ROAs than Anika, highlighting significant competition and the need for improved financial performance.

Financial Statements
Anika Therapeutics Inc 's Assets	$ 203 million	ANIK's Balance sheet
Anika Therapeutics Inc 's Income	$ 3 million	Quarterly ANIK's Income Statement
ANIK's Income by Division		See ANIK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	6.13 %	-26.43 %	-24.02 %	-2.59 %	-4.43 %
Total Assets in million	190	179	244	321	329
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-11	-56	-83	-15	4
Annual Return On Assets	-5.72 %	-31.45 %	-33.92 %	-4.63 %	1.26 %

ANIK's 5 Years Annual ROA >> Back to ANIK Management Effectiveness >> Compare ANIK ROA to its Competitors

More Return On Assets Ratios
ANIK's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANIK's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANIK's Competitors
Subscribers only: Roa for Anika Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ANIK's Customers

You may also want to know
ANIK's Roi	ANIK's Inventory Turnover Ratio	ANIK's Growth Rates	ANIK's Dividend Comparisons
	ANIK's Profitability Ratios	ANIK's Asset Turnover Ratio	ANIK's Dividend Growth
ANIK's Roe	ANIK's Valuation Ratios	ANIK's Financial Strength Ratios	ANIK's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T16:32:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.